Vanqua Bio
Jack has served as Vanqua Bio’s Chief Business Officer since April 2021. Prior to joining Vanqua Bio, he was an investment professional on the private equity team at OrbiMed Advisors LLC, a healthcare investment firm. Prior to OrbiMed, he was an equity research associate at Citi, covering medical device companies. He holds a B.A. cum laude in economics from Boston College.
Vanqua Bio
Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).